drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Gene-edited allogeneic universal CAR-T cell therapy targeting B-cell maturation antigen (BCMA) on malignant plasma cells to activate T-cell cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Biological Products
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Gene-edited allogeneic (universal) CAR-T cells engineered to express a BCMA-targeting chimeric antigen receptor. Binding to BCMA on malignant plasma cells triggers T-cell activation, cytokine release, and cytotoxic killing of tumor cells; gene edits reduce alloreactivity to enable off-the-shelf use.
drug_name
CT0594
nct_id_drug_ref
NCT05893693